Observational studyJournal of diabetes investigation2026
Diabetic peripheral neuropathy as measured using a point-of-care sural nerve conduction device is associated with a faster decline in renal function in patients with type 2 diabetes.
Observational study in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionDiabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus and may be linked to renal function decline. However, the prognostic value of point-of-care nerve conduction devices such as DPN-Check® for renal outcomes remains unclear. MATERIALS AND
methodsWe conducted a single-center retrospective observational study of 403 patients with diabetes (median follow-up 2.9 years) at Tokyo Metropolitan Ohkubo Hospital. DPN was assessed by DPN-Check® (amplitude [AMP] <5 μV or nerve conduction velocity [NCV] <42 m/s) and simplified diagnostic criteria (SDC). The primary outcome was annual eGFR decline, calculated by the linear least squares method; rapid decliners were defined as those with a decline ≥5 mL/min/1.73 m
resultsPatients with DPN diagnosed with DPN-Check® had a greater annual eGFR decline than those without (-2.26 vs. -0.81 mL/min/1.73 m
conclusionsDPN diagnosed by DPN-Check® was independently associated with accelerated renal function decline in patients with T2DM, even after adjusting for albuminuria. DPN-Check® may help identify patients at high risk for end-stage kidney disease and guide earlier intervention for both neuropathy and kidney disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.